基因编辑技术研发商Prime Medicine宣布普通股公开发行定价-动脉网

Prime Medicine Announces Pricing of Public Offering of Common Stock

GlobeNewswire 等信源发布 2026-11-11 02:40



可切换为仅中文







CAMBRIDGE, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the pricing of an underwritten public offering of 35,714,286 shares of its common stock at a public offering price of $3.50 per share.

马萨诸塞州剑桥，2026年11月10日（环球电讯社）——致力于提供新一代差异化一次性治愈性基因疗法的生物技术公司Prime Medicine, Inc.（纳斯达克股票代码：PRME）今日宣布，其承销公开发行35,714,286股普通股的定价为每股3.50美元。

Prime Medicine has also granted the underwriters a 30-day option to purchase up to an additional 5,357,142 shares of its common stock. The gross proceeds to Prime Medicine from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $125.0 million, excluding any exercise of the underwriters’ option to purchase additional shares.

Prime Medicine 还授予承销商一项为期30天的选择权，以额外购买最多5,357,142股其普通股。在不扣除承销折扣、佣金及发行费用，且不考虑承销商行使额外购股选择权的情况下，预计 Prime Medicine 从此次发行中获得的总收益约为1.25亿美元。

All of the shares of common stock in the offering are to be sold by Prime Medicine. The offering is expected to close on or about November 12, 2026, subject to the satisfaction of customary closing conditions..

本次发行中的所有普通股股份将由Prime Medicine出售。预计本次发行将于2026年11月12日或前后完成，具体取决于惯例交割条件的满足情况。

Jefferies, TD Cowen and Goldman Sachs & Co. LLC are acting as joint book-running managers for the offering. Oppenheimer & Co. and LifeSci Capital are acting as passive book-running managers for the offering.

杰富瑞、TD Cowen 和高盛集团有限责任公司担任本次发行的联席账簿管理人。奥本海默公司和 LifeSci Capital 担任本次发行的被动账簿管理人。

The shares of common stock are being offered by Prime Medicine pursuant to a shelf registration statement on Form S-3ASR (File No. 333-291348) filed with the U.S. Securities and Exchange Commission (SEC) on November 7, 2025, as amended by that certain Post-Effective Amendment No. 1 to Form S-3 (No. 333-291348) and that certain Post-Effective Amendment No.

Prime Medicine 正根据于2025年11月7日向美国证券交易委员会（SEC）提交的S-3ASR表格货架注册声明（档案号333-291348）发行普通股，该注册声明经S-3表格第1号生效后修正案（编号333-291348）及某项生效后修正案修订。

2 to Form S-3 (No. 333-291348), each filed with the SEC on March 3, 2026, and declared effective by the SEC on March 4, 2026. The offering is being made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement relating to and describing the terms of the offering has been filed with the SEC and is available on the SEC’s website at .

S-3表格第2号修正案（编号333-291348），均于2026年3月3日向美国证券交易委员会（SEC）提交，并于2026年3月4日获SEC宣布生效。本次发行仅通过构成注册声明一部分的书面招股说明书及招股说明书补充文件进行。一份与本次发行相关并描述其条款的初步招股说明书补充文件已提交至SEC，并可在SEC网站查阅。

www.sec.gov

。

The final prospectus supplement relating to and describing the final terms of the offering will be filed with the SEC and, when available, may be obtained from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; TD Securities (USA) LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at TDManualrequest@broadridge.com or Goldman Sachs & Co.

与本次发行最终条款相关并予以说明的最终招股说明书补充文件将向美国证券交易委员会（SEC）备案，并在备妥后通过以下方式获取：Jefferies LLC，收件人：股票承销团招股说明书部门，地址：520 Madison Avenue, New York, New York 10022，电话：(877) 821-7388，电子邮件：Prospectus_Department@Jefferies.com；TD Securities (USA) LLC，收件人：Broadridge Financial Solutions，地址：1155 Long Island Avenue, Edgewood, NY 11717，电子邮件：TDManualrequest@broadridge.com；或高盛公司（Goldman Sachs & Co.）。

LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, by telephone at (866) 471-2526, or by email at prospectus-ny@ny.email.gs.com..

有限责任公司，收件人：招股说明书部门，地址：纽约州纽约市西大街200号，邮编10282；电话：(866) 471-2526；电子邮件：prospectus-ny@ny.email.gs.com。

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction..

本新闻稿不构成出售要约或购买要约的招揽，也不得在任何州或司法管辖区进行此类证券的销售，如果在未根据该州或司法管辖区的证券法进行注册或资格认定之前，此类要约、招揽或销售将是非法的。

About Prime Medicine

关于Prime Medicine

Prime Medicine is a leading biotechnology company dedicated to creating and delivering the next generation of gene editing therapies to patients. The Company is deploying its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies.

Prime Medicine 是一家领先的生物技术公司，致力于为患者开发并提供下一代基因编辑疗法。该公司正利用其专有的 Prime Editing 平台——一种多功能、精准且高效的基因编辑技术——来开发一类具有差异化的新型一次性治愈性基因疗法。

Prime Editors are designed to make only the right edit at the right position within a gene while minimizing unwanted DNA modifications..

先导编辑器旨在仅在基因内的正确位置进行正确的编辑，同时最大限度地减少非预期的DNA修饰。

Prime Medicine is currently progressing a diversified portfolio of investigational therapeutic programs organized around its core areas of focus: liver, lung, and immunology and oncology. Across each core area, Prime Medicine is focused initially on a set of high-value programs, each targeting a disease with well-understood biology and a clearly defined clinical development and regulatory path..

Prime Medicine 目前正在推进一个多样化的研究性治疗项目组合，这些项目围绕其核心聚焦领域进行组织：肝脏、肺部以及免疫学与肿瘤学。在每个核心领域，Prime Medicine 最初专注于一系列高价值项目，每个项目均针对生物学机制明确、临床开发和监管路径清晰的疾病。

© 2026 Prime Medicine, Inc. All rights reserved. PRIME MEDICINE, the Prime Medicine logos, and PASSIGE are trademarks of Prime Medicine, Inc. All other trademarks referred to herein are the property of their respective owners.

Forward-Looking Statements

前瞻性陈述

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements about Prime Medicine's beliefs and expectations regarding: the expected gross proceeds from the public offering and the timing and closing of the public offering.

本新闻稿包含经修订的《1995年私人证券诉讼改革法案》所定义的“前瞻性陈述”，包括但不限于关于Prime Medicine对以下事项的信念和预期的明示或暗示陈述：公开发行预计募集的毛收益以及公开发行的时间安排和成交情况。

The words 'may,' 'might,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'estimate,' 'seek,' 'predict,' 'future,' 'project,' 'potential,' 'continue,' 'target' and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words..

“可能”、“或许”、“将”、“能够”、“会”、“应当”、“预期”、“计划”、“预计”、“打算”、“相信”、“估计”、“寻求”、“预测”、“未来”、“规划”、“潜在”、“继续”、“目标”等词语或类似表述旨在识别前瞻性陈述，尽管并非所有前瞻性陈述都包含这些识别性词语。

Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions and satisfaction of customary closing conditions related to the public offering.

本新闻稿中的任何前瞻性陈述均基于管理层当前的预期和信念，并受多种风险、不确定性和重要因素的影响，这些因素可能导致实际事件或结果与本新闻稿中任何前瞻性陈述所明示或暗示的内容存在重大差异，包括但不限于与市场状况相关的不确定性，以及与公开发行相关的惯常交割条件是否得到满足的不确定性。

These and other risks and uncertainties are described in greater detail in the section entitled 'Risk Factors' in Prime Medicine's most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, and any of its subsequent filings with the SEC. In addition, any forward-looking statements represent Prime Medicine's views only as of today and should not be relied upon as representing its views as of any subsequent date.

这些及其他风险和不确定性在Prime Medicine最新的10-K年度报告、截至2026年6月30日的季度10-Q季度报告以及其随后向美国证券交易委员会（SEC）提交的任何文件中题为“风险因素”的章节中有更详细的描述。此外，任何前瞻性陈述仅反映Prime Medicine截至本日的观点，不应被视为代表其在任何后续日期的观点。

Prime Medicine explicitly disclaims any obligation to update any forward-looking statements subject to any obligations under applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements..

Prime Medicine 明确声明，除适用法律规定的义务外，不承担任何更新前瞻性陈述的义务。对于任何此类前瞻性陈述的准确性，不作任何明示或暗示的陈述或保证。

Investor and Media Contacts

投资者与媒体联系人

Gregory Dearborn

格雷戈里·迪尔伯恩

Prime Medicine

857-209-0696

gdearborn@primemedicine.com

Hannah Deresiewicz

汉娜·德雷谢维奇

Precision AQ

精准空气质量